Tagged as: Aflibercept

Recent PTAB Developments for Regeneron’s Aflibercept Formulation Patent

Earlier this month, a Patent Trial and Appeal Board (“PTAB”) panel denied institution of two petitions that were filed separately by Samsung Bioepis (IPR2025-00176) and Formycon (IPR2025-00233) for inter partes review (“IPR”) of Regeneron’s U.S. Patent No. 11,084,865 (the “’865 patent”).  The ’865 patent issued on August 10, 2021 and is…

Read More